Streetbeat News

ANTX

AN2 Therapeutics, Inc.

https://www.an2therapeutics.com

Industry

Biotechnology

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Open

1.00

Mkt cap

30M

Volume

1.2M

High

1.04

P/E Ratio

-0.50

52-wk high

22.22

Low

0.99

Div yield

N/A

52-wk low

0.87

JMP Securities analyst Roy Buchanan maintains a Market Outperform rating on AN2 Therapeutics (NASDAQ:ANTX) but lowers the price target from $6 to $3.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 11:00 am

AN2 Therapeutics shares are trading lower after the company announced the discontinuation of its EBO-301 study following topline results from its Phase 2 part of the study in treatment-refractory patients with MAC lung disease.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:39 pm

AN2 Therapeutics announced the discontinuation of its EBO-301 Phase 2/3 study evaluating Epetraborole for treatment-refractory Mycobacterium avium Complex (MAC) lung disease following topline results. The company will shift focus to its internal boron chemistry platform and ongoing pipeline programs. The restructuring and cost savings from discontinuing the study are expected to extend the company's cash runway through 2027.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:37 pm

Leerink Partners has upgraded AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform, as per analyst Joseph Schwartz.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2024 | 2:58 pm

The article highlights the performance of 12 health care stocks during Friday's after-market session. Notable gainers include Kineta (KA), iSpecimen (ISPC), ENDRA Life Sciences (NDRA), Brainstorm Cell (BCLI), Bullfrog AI Holdings (BFRG), and Can Fite Biofarma (CANF). On the losing side, Nexalin Technology (NXL), Scinai Immunotherapeutics (SCNI), Ontrak (OTRK), AN2 Therapeutics (ANTX), CERo Therapeutics Holdings (CERO), and Renovaro (RENB) saw declines.

Portfolio Pulse from Benzinga Insights

June 14, 2024 | 8:31 pm

Evercore ISI Group analyst Liisa Bayko maintains an In-Line rating on AN2 Therapeutics (NASDAQ:ANTX) but lowers the price target from $7 to $2.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 3:51 pm

In Thursday's after-market session, several healthcare stocks showed notable movements. Orgenesis, AN2 Therapeutics, GRI Bio, NuCana, Stoke Therapeutics, and Candel Therapeutics were among the gainers, with increases ranging from 4.99% to 8.5%. On the downside, Acorda Therapeutics, Aesthetic Medical Intl, Eiger BioPharmaceuticals, Coeptis Therapeutics, iSpecimen, and WAVE Life Sciences experienced declines between 4.96% and 8.9%. These movements reflect the dynamic nature of the healthcare sector in the stock market.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 8:31 pm

JMP Securities analyst Roy Buchanan upgraded AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Market Outperform, setting a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 6:05 pm

Oppenheimer analyst Jeff Jones has reiterated a Perform rating on AN2 Therapeutics (NASDAQ:ANTX), maintaining the company's current stock performance outlook.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:13 pm

AN2 Therapeutics (NASDAQ:ANTX) reported Q4 earnings with losses of $(0.57) per share, surpassing the analyst consensus estimate of $(0.76) by 25%. This represents a 6.56% improvement over the previous year's losses of $(0.61) per share.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:49 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.